Rate My Professor Simon Royce

Royce contributes to multiple funded projects, such as establishing non-invasive screening for early detection of silicosis (2023-2025), developing a novel human model for anti-fibrotic drug screening in silicosis funded by iCare NSW (2023-2026), blocking harmful lung damage during acute COPD exacerbations (2023-2025), and exploring free fatty acid receptors as bronchodilator targets in severe asthma (NHMRC-funded, 2020-2022). He has supervised doctoral students including Dr. Hamish Philpott, Dr. Krupesh Patel, Dr. Maggie Lam, Dr. Vivian Mao, Dr. Amlan Chakraborty, Ms. Claudia Sim, and Mr. Mahesh Dharmakumara. His key publications encompass 'Sulforaphane prevents and reverses allergic airways disease in mice via anti-inflammatory, antioxidant, and epigenetic mechanisms' (2022, Cellular and Molecular Life Sciences), 'Mesenchymal stem cells and serelaxin synergistically abrogate established airway fibrosis in an experimental model of chronic allergic airways disease' (2015, Stem Cell Research & Therapy), 'Serelaxin improves the therapeutic efficacy of RXFP1-expressing mesenchymal stem cells in experimental pulmonary fibrosis' (2019, British Journal of Pharmacology), 'The novel AT2 receptor ligand, β-Pro7 Ang III, induces equivalent anti-fibrotic effects to Compound 21' (2025, Clinical Science), and 'Human bone marrow mesenchymal stem cell-derived extracellular vesicles induce inverse dose-dependent anti-fibrotic effects' (2025, Biomedicine & Pharmacotherapy). Royce co-holds US Patent 11471493 for the method using induced pluripotent stem cell-derived mesenchymal stem cells to treat asthma. His research supports SDG 3: Good Health and Well-being and has garnered over 4,300 citations.